Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL GILMAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1215943634
CMS profile
282465
Location
WYNNEWOOD, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$568.35

28 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $568.35 28

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $216.20 8
Genentech USA, Inc. $126.67 8
EISAI INC. $110.03 5
Lilly USA, LLC $43.72 3
Merck Sharp & Dohme Corporation $35.20 2
Janssen Biotech, Inc. $21.27 1
Astellas Pharma US Inc $15.26 1

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL GILMAN

NPI 1215943634 · CMS profile ID 282465

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WYNNEWOOD, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215943634?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL GILMAN, NPI 1215943634, CMS profile ID 282465. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215943634?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PAUL GILMAN, NPI 1215943634, CMS profile ID 282465. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215943634?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PAUL GILMAN, NPI 1215943634, CMS profile ID 282465, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215943634?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

28 matching records · $568.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 28 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–28 of 28.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $21.2012/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697023835 CMS
EISAI INC. $22.9911/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697043955 CMS
Lilly USA, LLC $11.4411/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658065517 CMS
EISAI INC. $18.3610/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697015975 CMS
Celgene Corporation $19.3709/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672924203 CMS
EISAI INC. $24.4609/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697012341 CMS
Astellas Pharma US Inc $15.2608/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655575265 CMS
Celgene Corporation $13.8307/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672854467 CMS
Genentech USA, Inc. $14.3907/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681422953 CMS
Celgene Corporation $90.3205/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673018211 CMS
Janssen Biotech, Inc. $21.2705/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658445605 CMS
Genentech USA, Inc. $19.7005/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681246667 CMS
Genentech USA, Inc. $13.2504/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681306901 CMS
Lilly USA, LLC $13.3804/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658079339 CMS
Celgene Corporation $15.1404/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672758651 CMS
Celgene Corporation $18.5504/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672872330 CMS
Merck Sharp & Dohme Corporation $17.5704/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695455761 CMS
Celgene Corporation $16.3703/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672761895 CMS
Genentech USA, Inc. $14.9802/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681278241 CMS
Genentech USA, Inc. $18.5202/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681239335 CMS
Lilly USA, LLC $18.9002/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658065519 CMS
EISAI INC. $23.0202/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696998213 CMS
Merck Sharp & Dohme Corporation $17.6301/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695247955 CMS
Celgene Corporation $20.5101/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672725015 CMS
Genentech USA, Inc. $19.2301/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681304329 CMS
Celgene Corporation $22.1101/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672715489 CMS
Genentech USA, Inc. $15.6501/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681153921 CMS
Genentech USA, Inc. $10.9501/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681221725 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $568.35 28
PY2020 $34.49 2
PY2021 $159.26 4
PY2022 $77.89 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $45,338.69 23
PY2024 Recipient $2,757.76 1
PY2024 Principal investigator $167,078.01 59
PY2023 Principal investigator $76,233.25 12
PY2022 Principal investigator $106,224.88 15
PY2021 Principal investigator $45,160.00 2
PY2020 Principal investigator $22,430.00 2
PY2019 Principal investigator $17,343.03 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $10,914.51 12/31/2024 Non-covered Recipient Entity
Lankenau Medical Center
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy SBRT with or without Pembrolizumab MK-3475 in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer NSCLC KEYNOTE-867 No dispute reported 06/30/2026 1136414317
Principal investigator 1 Tolmar, Inc. $2,957.50 12/13/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study No dispute reported 06/30/2026 1141551489
Principal investigator 1 Tolmar, Inc. $1,171.10 11/22/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study No dispute reported 06/30/2026 1141551493
Principal investigator 1 Tolmar, Inc. $2,652.30 11/01/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551467
Principal investigator 1 Tolmar, Inc. $2,652.30 11/01/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551469
Principal investigator 1 Tolmar, Inc. $2,022.30 11/01/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551471
Principal investigator 1 GlaxoSmithKline, LLC. $2,925.00 10/17/2024 Non-covered Recipient Entity
PARTNERS IN INNOVATION EDUCATION AND RESEARCH CONSORTIUM
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1127522292
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 10/17/2024 Non-covered Recipient Entity
PARTNERS IN INNOVATION EDUCATION AND RESEARCH CONSORTIUM
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1127522294
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 10/17/2024 Non-covered Recipient Entity
PARTNERS IN INNOVATION EDUCATION AND RESEARCH CONSORTIUM
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1127522296
Principal investigator 1 GlaxoSmithKline, LLC. $5,485.00 10/17/2024 Non-covered Recipient Entity
PARTNERS IN INNOVATION EDUCATION AND RESEARCH CONSORTIUM
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1127536582
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 10/17/2024 Non-covered Recipient Entity
PARTNERS IN INNOVATION EDUCATION AND RESEARCH CONSORTIUM
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1127536584
Principal investigator 1 GlaxoSmithKline, LLC. $15,000.00 10/17/2024 Non-covered Recipient Entity
PARTNERS IN INNOVATION EDUCATION AND RESEARCH CONSORTIUM
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1127536586
Principal investigator 1 Tolmar, Inc. $750.00 10/11/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study No dispute reported 06/30/2026 1141551487
Principal investigator 1 Tolmar, Inc. $105.00 10/11/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study No dispute reported 06/30/2026 1141551491
Principal investigator 1 Tolmar, Inc. $12,800.00 10/11/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study No dispute reported 06/30/2026 1141551495
Principal investigator 1 Tolmar, Inc. $2,397.50 09/13/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study No dispute reported 06/30/2026 1141551485
Principal investigator 1 Incyte Corporation $1,980.00 09/04/2024 Covered Recipient Teaching Hospital
Lankenau Medical Center
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1134668685
Principal investigator 1 Incyte Corporation $1,500.00 09/04/2024 Covered Recipient Teaching Hospital
Lankenau Medical Center
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1134668687
Principal investigator 1 SANOFI US SERVICES INC. $14,500.00 09/04/2024 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors No dispute reported 06/30/2026 1128716575
Principal investigator 1 Tolmar, Inc. $2,092.30 08/09/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551401
Principal investigator 1 Tolmar, Inc. $1,260.00 08/09/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551403
Principal investigator 1 Tolmar, Inc. $1,722.70 08/09/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551405
Principal investigator 1 Tolmar, Inc. $280.00 08/09/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551407
Principal investigator 1 Tolmar, Inc. $2,652.30 08/09/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551409
Principal investigator 1 Tolmar, Inc. $2,092.30 08/09/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551411
Principal investigator 1 Tolmar, Inc. $2,092.30 08/09/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551413
Principal investigator 1 Tolmar, Inc. $1,722.70 08/09/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551415
Principal investigator 1 Incyte Corporation $275.00 07/26/2024 Covered Recipient Teaching Hospital
Lankenau Medical Center
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1134668679
Principal investigator 1 Incyte Corporation $750.00 07/26/2024 Covered Recipient Teaching Hospital
Lankenau Medical Center
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1134668681
Principal investigator 1 Incyte Corporation $4,000.00 07/26/2024 Covered Recipient Teaching Hospital
Lankenau Medical Center
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1134668683
Principal investigator 1 Tolmar, Inc. $168.00 07/12/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551417
Principal investigator 1 Tolmar, Inc. $168.00 07/12/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551419
Principal investigator 1 Tolmar, Inc. $168.00 07/12/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551421
Principal investigator 1 Tolmar, Inc. $168.00 07/12/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551423
Principal investigator 1 Tolmar, Inc. $168.00 07/12/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551425
Principal investigator 1 Tolmar, Inc. $168.00 07/12/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551427
Principal investigator 1 Merck Sharp & Dohme LLC $14,563.30 07/08/2024 Non-covered Recipient Entity
Lankenau Medical Center
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy SBRT with or without Pembrolizumab MK-3475 in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer NSCLC KEYNOTE-867 No dispute reported 06/30/2026 1136414312
Principal investigator 1 Tolmar, Inc. $1,171.10 06/07/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study No dispute reported 06/30/2026 1141551481
Principal investigator 1 Tolmar, Inc. $1,012.20 06/07/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study No dispute reported 06/30/2026 1141551483
Principal investigator 1 Incyte Corporation $950.00 05/17/2024 Non-covered Recipient Entity
PARTNERS IN INNOVATION, EDUCATION, AND RESEARCH CONSORTIUM, LLC
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1134709215
Principal investigator 1 Tolmar, Inc. $2,562.70 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551429
Principal investigator 1 Tolmar, Inc. $1,260.00 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551431
Principal investigator 1 Tolmar, Inc. $1,722.70 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551433
Principal investigator 1 Tolmar, Inc. $2,092.30 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551435
Principal investigator 1 Tolmar, Inc. $3,760.40 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551437
Principal investigator 1 Tolmar, Inc. $5,020.40 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551439
Principal investigator 1 Tolmar, Inc. $2,562.70 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551441
Principal investigator 1 Tolmar, Inc. $2,652.30 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551443
Principal investigator 1 Tolmar, Inc. $280.00 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551445
Principal investigator 1 Tolmar, Inc. $3,760.40 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551447
Principal investigator 1 Tolmar, Inc. $5,020.40 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551449
Principal investigator 1 Tolmar, Inc. $1,722.70 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551451
Principal investigator 1 Tolmar, Inc. $2,538.90 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551453
Principal investigator 1 Tolmar, Inc. $1,260.00 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551455
Principal investigator 1 Tolmar, Inc. $280.00 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551457
Principal investigator 1 Tolmar, Inc. $3,760.40 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551459
Principal investigator 1 Tolmar, Inc. $2,562.70 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551461
Principal investigator 1 Tolmar, Inc. $280.00 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551463
Principal investigator 1 Tolmar, Inc. $2,022.30 04/19/2024 Non-covered Recipient Entity
Lankenau Institute for Medical Research
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer No dispute reported 06/30/2026 1141551465
Recipient Eli Lilly and Company $2,757.76 03/26/2024 Covered Recipient Physician SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1137349041